Zealand Pharma (Denmark) Performance
| ZEAL Stock | DKK 723.00 15.50 2.10% |
The firm maintains a market beta of 0.86, which attests to possible diversification benefits within a given portfolio. Zealand Pharma returns are very sensitive to returns on the market. As the market goes up or down, Zealand Pharma is expected to follow. At this point, Zealand Pharma AS has a negative expected return of -0.22%. Please make sure to check out Zealand Pharma's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if Zealand Pharma AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zealand Pharma AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 960.2 M | |
| Total Cashflows From Investing Activities | -18.1 M |
Zealand |
Zealand Pharma Relative Risk vs. Return Landscape
If you would invest 86,050 in Zealand Pharma AS on August 28, 2024 and sell it today you would lose (13,750) from holding Zealand Pharma AS or give up 15.98% of portfolio value over 90 days. Zealand Pharma AS is generating negative expected returns and assumes 2.9532% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than Zealand, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Zealand Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zealand Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zealand Pharma AS, and traders can use it to determine the average amount a Zealand Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0759
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ZEAL |
Estimated Market Risk
| 2.95 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Zealand Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zealand Pharma by adding Zealand Pharma to a well-diversified portfolio.
Zealand Pharma Fundamentals Growth
Zealand Stock prices reflect investors' perceptions of the future prospects and financial health of Zealand Pharma, and Zealand Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zealand Stock performance.
| Return On Equity | -1.44 | |||
| Return On Asset | -0.48 | |||
| Operating Margin | (3.82) % | |||
| Current Valuation | 10.33 B | |||
| Shares Outstanding | 51.28 M | |||
| Price To Earning | 12.66 X | |||
| Price To Book | 27.77 X | |||
| Price To Sales | 36.73 X | |||
| Revenue | 292.57 M | |||
| EBITDA | (982.6 M) | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 29.66 X | |||
| Total Debt | 647.91 M | |||
| Debt To Equity | 0.10 % | |||
| Book Value Per Share | 7.91 X | |||
| Cash Flow From Operations | (1.21 B) | |||
| Earnings Per Share | (23.13) X | |||
| Total Asset | 2.07 B | |||
| Retained Earnings | 154 M | |||
| Current Asset | 517 M | |||
| Current Liabilities | 54 M | |||
About Zealand Pharma Performance
By examining Zealand Pharma's fundamental ratios, stakeholders can obtain critical insights into Zealand Pharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Zealand Pharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Zealand Pharma AS, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. The company was founded in 1997 and is headquartered in Copenhagen, Denmark. Zealand Pharma operates under Biotechnology classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 360 people.Things to note about Zealand Pharma AS performance evaluation
Checking the ongoing alerts about Zealand Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zealand Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zealand Pharma AS generated a negative expected return over the last 90 days | |
| The company reported the revenue of 292.57 M. Net Loss for the year was (1.02 B) with profit before overhead, payroll, taxes, and interest of 173.75 M. | |
| Zealand Pharma AS has accumulated about 1.28 B in cash with (1.21 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 29.66. | |
| Roughly 56.0% of the company outstanding shares are owned by institutional investors |
- Analyzing Zealand Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zealand Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Zealand Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zealand Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zealand Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zealand Pharma's stock. These opinions can provide insight into Zealand Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Zealand Stock
Zealand Pharma financial ratios help investors to determine whether Zealand Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zealand with respect to the benefits of owning Zealand Pharma security.